Publications by authors named "Amy Tilley"

Claim this Profile
U
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
Brian L Heiss, Elaine Chang, Xin Gao, Tien Truong, Michael H Brave, Amy Tilley

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, -Mutated Advanced or Metastatic Breast Cancer.
Mirat Shah, Hima Lingam, Xin Gao, Haley Gittleman, Mallorie H Fiero, Amy Tilley

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Anand Shah, Erik Bloomquist, Shenghui Tang, Wentao Fu, Youwei Bi, Amy Tilley

Clin Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Amanda J Walker, Suparna Wedam, Laleh Amiri-Kordestani, Erik Bloomquist, Shengui Tang, Amy Tilley

Clin Cancer Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Julia A Beaver, Laleh Amiri-Kordestani, Rosane Charlab, Wei Chen, Todd Palmby, Amy Tilley

Clin Cancer Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
Laleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, Shenghui Tang, Amy Tilley

Clin Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Paul G Kluetz, Yang-Min Ning, V Ellen Maher, Lijun Zhang, Shenghui Tang, Amy Tilley

Clin Cancer Res· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Gideon M Blumenthal, Nancy S Scher, Patricia Cortazar, Somesh Chattopadhyay, Shenghui Tang, Amy Tilley

Clin Cancer Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis